MARKET

CNAT

CNAT

Conatus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3100
+0.0150
+5.08%
After Hours: 0.3001 -0.0099 -3.19% 18:14 04/03 EDT
OPEN
0.2985
PREV CLOSE
0.2950
HIGH
0.3100
LOW
0.2931
VOLUME
56.45K
TURNOVER
--
52 WEEK HIGH
1.440
52 WEEK LOW
0.2303
MARKET CAP
10.28M
P/E (TTM)
-0.9030
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CNAT stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.

EPS

CNAT News

More
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Conatus Pharmaceuticals reports Q4 results
  • seekingalpha · 03/12 01:55
  • Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update
  • GlobeNewswire · 03/11 21:45
  • Conatus Pharmaceuticals Q4 EPS $(0.08) Up From $(0.13) YoY, Sales $526K Down From $7.409M YoY
  • Benzinga · 03/11 20:48

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CNAT

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
More

Webull offers kinds of Conatus Pharmaceuticals Inc stock information, including NASDAQ:CNAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNAT stock news, and many more online research tools to help you make informed decisions.